[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucose-control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucose-control":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,83,112,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100565284","feasibility-and-plausible-effectiveness-of-a-lifestyle-intervention-in-kidney-transplant-recipients-heal-100565284",false,"NCT06640179","Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)","Prevention of Weight Gain and Impaired Glucose Metabolism Post Kidney Transplantation: A Pilot and Feasibility Study","HEAL","Inclusion Criteria:\n\n* Receiving a kidney transplant within the prior 3-5 months, with the transplant received from a deceased donor or living donor. NOTE: The patient will be eligible for randomization at 3 months following the kidney transplant, or at a subsequent time once clearance from the kidney transplant physician is given, provided that the time does not exceed 5 months following the kidney transplant.\n* Both males and females of all race\u002Fethnic groups are eligible for participation in this study.\n* \\>=18 years of age.\n* Body mass index (BMI) \\>22 kg\u002Fm2. There is no maximal BMI provided that the weight does not exceed the weight allowance of the dual-energy x-ray absorptiometer (DXA) that is used to assess body composition (maximal weight for the DXA is 350 pounds).\n* Ability to provide informed consent prior to participation in this study.\n* Ability to provide clearance from their kidney transplant physician to engage in the diet and physical activity components of the proposed intervention and to safely complete the proposed outcome measures.\n* Ability to walk for exercise.\n\nExclusion Criteria:\n\n* Females who are pregnant, breastfeeding, or reporting a planned pregnancy during the study period. Female participants of childbearing age who are not currently taking contraceptive medication, are not post-menopausal, or have not been surgically sterilized will need to agree to use a double barrier method of contraception.\n* History of bariatric surgery.\n* Currently prescribed an anti-obesity medication.\n* Report current medical condition or treatment for a medical condition that could affect body weight. These may include the following: diabetes mellitus; hyperthyroidism; inadequately controlled hypothyroidism; chronic liver disease; cancer; gastrointestinal disorders including ulcerative colitis, Crohn's disease, or malabsorption syndromes; etc.\n* Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).\n* Resting systolic blood pressure of \\>=160 mmHg or resting diastolic blood pressure of \\>=100 mmHg or not on a stable medical treatment to control hypertension (stable dose is defined as the same dose and type of medication for a period of at least 6 months).\n* Eating disorders that would contraindicate modifying eating or physical activity behaviors.\n* Alcohol or substance abuse.\n* Currently treated for psychological issues (i.e., depression, bipolar disorder, etc.) that is accompanied by the following: 1) not on a stable dose of medications for treatment within the previous 12 months, or 2) hospitalized for depression within the previous 5 years.\n* Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether if it is feasible to implement a study of patients receiving kidney transplantation, to learn if these patients will complete selective outcomes measurements, and to examine if a lifestyle intervention may assist with preventing weight gain compared to standard medical care. The main questions it aims to answer are:\n\n* Is it feasible to recruit and retain patients who have undergone kidney transplantation into a study to compare standard medical care to standard medical care plus a lifestyle intervention focused on prevention of weight gain?\n* Will participants engage in the interventions and be compliant to the components of the interventions?\n* Will there be any difference between the interventions between the interventions for the occurrence of adverse events specific to kidney transplantation?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on preventing weight gain compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on body composition compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on fasting glucose compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on fasting insulin compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on insulin sensitivity compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on physical function compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on health-related quality of life compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on changes in dietary intake compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on physical activity and sedentary behavior compared to standard medical care alone?\n\nParticipants will:\n\n* Participants will continue with their standard medical care following kidney transplantation.\n* Participants only receiving standard medical care will also complete brief monitoring visits at week 6, 12, and 18.\n* Participants receiving the lifestyle intervention will attend weekly intervention sessions and will be recommended to modify their diet and physical activity behaviors in an effort to prevent weight gain.\n* Participants will complete outcome measurements as the start of the study and again after 6 months in the study.\n* After 6 months in the study, participants will also complete a brief intervention and answer other questions about their experience in the study.",[27,28,29],"Kidney Transplant","Overweight or Obese Adults","Glucose Control",[31,32,33,34,35],"kidney transplant","overweight","obesity","glucose control","weight control","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2024-12-17",{"date":44,"type":21},"2027-03-01",{"name":46,"class":47},"University of Kansas Medical Center","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100638562","eating-almonds-before-a-meal-to-control-blood-sugar-100638562","NCT07603739","Eating Almonds Before a Meal to Control Blood Sugar","Interindividual Variability in the Effect of Premeal Almond Supplementation on Glycemic Control - a Double Crossover Study","NUTS","Inclusion Criteria:\n\n* Adults aged 25-50 years\n* Females over 40 years must have had a cycle in the last 6 months\n* Body mass index (BMI) at least 18.5 and at most 55.0 kg\u002Fm2\n* Impaired blood glucose by at least one of the following criteria:\n* Fasting blood glucose at least 100 mg\u002FdL (5.6 mmol\u002FL) and less than 125 mg\u002FdL (6.9 mmol\u002FL)\n* HbA1c at least 5.7% and less than 6.5%\n* Willing and able to comply with study foods\n* Willing and able to ingest acetaminophen as part of study procedures\n* Able to read, speak, and understand English\n\nExclusion Criteria:\n\n* Weight change ≥5% in past 6 months, actively trying to lose weight, or unwilling to remain weight stable throughout the study based on self-report\n* Recent history within past 12 months of medical provider-diagnosed cardiovascular, renal, or liver disease that required treatment\n* Current or past diagnosis of cancer (except skin cancer) in the last 5 years\n* Current or past diagnosis of type 1 or type 2 diabetes\n* Recent history within past 12 months of medical provider-diagnosed gastrointestinal or neurological disorders if not managed\u002Fstable for at least 3 months (with or without treatment)\n* Recent history within past 12 months of medical provider-diagnosed psychiatric disorders including eating disorders or severe depression if not managed\u002Fstable for at least 3 months (with or without treatment)\n* Food allergies or other reasons preventing consumption of study foods\n* Any glucose-lowering medication except biguanides (e.g., Metformin) if stable for at least 3 months or incretins (i.e., GLP-1RA-based) if stable for at least 3 months\n* Current smoking or vaping or history of smoking or vaping in the past 6 months\n* Binge and\u002For heavy drinking (i.e., \\>3 drinks on any given occasion and\u002For \\>7 drinks\u002Fweek)\n* Currently pregnant or planning to become pregnant or breastfeed in the next 3 months by self-report",true,"25 Years","50 Years",{"count":61,"type":21},25,[24],"The goal of this study is to learn whether eating a small serving of almonds before meals can improve blood sugar control in adults who have early signs of problems with blood sugar regulation. The main questions it aims to answer are:\n\n1. Does eating almonds before a meal reduce the rise in blood sugar after eating?\n2. Do some people consistently benefit more than others from eating almonds before meals?",[29,65,66,67],"Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)","Precision Medicine","Nutrition",[67,66,69,29,70,71,72],"Precision Nutrition","Impaired Glucose Tolerance","Insulin Resistance","Prediabetes","NOT_YET_RECRUITING","2026-05-16",{"date":76,"type":40},"2026-05-22",{"date":78,"type":21},"2026-06",{"date":80,"type":21},"2028-07",{"name":82,"class":47},"Pennington Biomedical Research Center",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":48},"100537115","effect-of-changes-in-carbohydrate-intake-patterns-on-glucose-control-in-patients-with-type-1-diabetes-100537115","NCT06273631","Effect of Changes in Carbohydrate Intake Patterns on Glucose Control in Patients With Type 1 Diabetes","Inclusion Criteria:\n\n1. Those who agree to participate in the study and sign informed consent;\n2. Diagnosis of type 1 diabetes mellitus (ADA2024);\n3. Age of 18\\~70 years;\n4. Dependent on exogenous insulin therapy, the treatment plan remains unchanged within 2 months (the type of insulin cannot be changed, and the dose can be adjusted according to plasma glucose);\n5. Body mass index (BMI) of 18\\~25kg\u002Fm2;\n6. HbA1c ≤11%;\n\nExclusion Criteria:\n\n1. Honeymooners with type 1 diabetes mellitus;\n2. Women who are pregnant or plan to become pregnant;\n3. Patients who are vegetarians or are undergoing weight loss;\n4. Patients who are users of oral hypoglycemic drugs (alpha-glucosidase inhibitors, DPP-IV inhibitors, etc.);\n5. Patients who are users of glucocorticoids within 30 days;\n6. History of severe food allergy;\n7. Patients with acute complications such as DKA or HHS within six months;\n8. Patients with gastroparesis, inflammatory bowel disease and other complications;\n9. Patients with large albuminuria(albumin-to-creatinine ratio\\>34.09mg\u002Fmmol) and renal insufficiency(creatinine\\>200umol\u002FL);\n10. Patients with uncontrolled hyperthyroidism and hypothyroidism(Uncontrolled hyperthyroidism is defined as abnormal TSH and T4. Uncontrolled hypothyroidism is defined as TSH \\> 10mIU\u002FL.);\n11. History of heart disease, coronary heart disease and arrhythmia;\n12. Serious of liver dysfunction (ALT or AST\\>3 times the upper limit of normal);\n13. History of malignant tumors; History of tumors or surgeries affecting digestion and nutrient absorption; Patients with a history of benign tumors, which is judged by the physician to be not suitable;\n14. Patients with uncontrolled other immune system diseases or uncontrolled infections;\n15. Alcohol abuse, drug abuse, mental disorders or other conditions unfit to be an observer in drug tests;\n16. Patients with any disease likely to interfere with study participation or evaluation.","70 Years",{"count":91,"type":21},80,[24],"The blood glucose fluctuates greatly in T1DM patients, especially in the middle and late stages of the disease, and carbohydrate (CHO) is the main determinant of postprandial glucose response (PGR). Based on the previous investigation to understand how nutritional habits affect blood glucose control, we will conduct dietary intervention studies in T1DM patients to explore whether the adjustment of dietary pattern is beneficial to blood glucose control, and further explore the relevant mechanism through the detection of related metabolic indicators.",[95,96,29],"Type 1 Diabetes","Diet Intervention",[98,99,100,101,102],"dietary fiber","autoimmunity","metabolomics","intestinal microbiota","time in range","2026-04-15",{"date":105,"type":40},"2026-04-20",{"date":107,"type":40},"2024-08-01",{"date":109,"type":21},"2027-12-31",{"name":111,"class":47},"Yang Tao",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":57,"sex":118,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":48},"100626239","impact-of-supplementation-in-improving-metabolic-health-outcomes-ismos-study-100626239","NCT07433049","Impact of Supplementation in Improving Metabolic Health Outcomes (ISMOS) Study","Inclusion Criteria:\n\n* Women aged 40-60 years old\n* Chinese, Malay or Indian\n* BMI between 23.0-35.0 kg\u002Fm2\n* Proficient in English language\n* Willing to comply with study protocol \\& provide informed consent\n\nExclusion Criteria:\n\n* Pregnant or planning a pregnancy\n* Diagnosis with Diabetes, Polycystic Ovary Syndrome (PCOS), autoimmune diseases, chronic organ failure, severe heart disease, eating disorders and\u002For other medical conditions which in the PI's judgment which may affect study outcomes\n* Fasting glucose value ≥ 7.0 mmol\u002FL\n* Active cancer or treatment of cancer in the last 3 years\n* Participating in other nutritional intervention studies\n* Taking oral corticosteroids, anti-psychotic and\u002For weight loss drugs\n* Having planned hospitalization in the next 12 months\n* Planning to have major diet changes in the next 12 months\n* Taking a medically prescribed supplement(s) that contains 3 or more of the ingredients of the study product\n* Taking a non-prescribed supplement(s) that contains 3 or more of the ingredients of the study product in the last 1 month","FEMALE","40 Years","60 Years",{"count":122,"type":21},400,[24],"This study investigates the role of multivitamin and multimineral (MVM) supplementation in improving metabolic, musculoskeletal, and mental health among midlife Asian women aged 40-60 years, a critical period marked by hormonal and physiological transitions from pre- to post-menopause. Evidence from the GUSTO cohort in Singapore has shown that higher plasma levels of vitamins B6, B9, B12, and D are associated with better metabolic profiles, insulin sensitivity, and mental wellbeing, while deficiencies are linked to increased metabolic and psychological risks. Given that vitamin insufficiency and central obesity are highly prevalent among Asian women even at lower BMI, this randomized, double-blind, placebo-controlled trial will evaluate whether 12 months of daily MVM supplementation can reduce MetaboAge and improve metabolic, mental, and muscle health outcomes compared with placebo. Findings will inform preventive strategies for extending health span and mitigating chronic disease risks among midlife women in Asia.",[29,126,127,128],"Mental Health","Musculoskeletal Health","Body Composition",[130,131,132,133,134],"Multivitamin and mineral supplementation","Women","Metabolic health","Mental health","Muscle health","2026-02-19",{"date":137,"type":40},"2026-02-25",{"date":139,"type":40},"2026-01-20",{"date":141,"type":21},"2028-01",{"name":143,"class":47},"Institute for Human Development and Potential (IHDP), Singapore",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":153,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100602859","need-driven-treatment-of-the-patients-with-type-1-diabetes-100602859","NCT07128992","Need-driven Treatment of the Patients With Type 1 Diabetes","The Impact of Need-driven Treatment of Insulin-Deficient Diabetes on the Care Events, Glycemic Control, Risk Factors, and Complications in the Pirkanmaa Wellbeing Services County, Finland","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of type 1 diabetes\n* Treatment with multiple daily injections or insulin pump therapy\n* Duration of diabetes ≥ 1 year\n* Good glycemic control over the previous two weeks, defined as:\n* HbA1c \\\u003C 53 mmol\u002Fmol\n* Time in Range (TIR) \\> 70%\n* Time Below Range (TBR) \\\u003C 4%\n* Time Above Range (TAR) \\\u003C 25%\n* Use of a continuous glucose monitoring system connected via a smartphone application\n* Under specialist diabetes care within the Pirkanmaa Wellbeing Services County (Pirha)\n* Willing to accept remote diabetes care by granting the diabetes team at Tampere University Hospital access to glucose data\n* No need for regular specialist care due to other medical conditions\n* Provides informed consent to participate in the study\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Duration of diabetes \\\u003C 1 year\n* Pregnancy\n* Not using multiple daily injections or insulin pump therapy\n* Not using a continuous glucose monitoring system\n* Does not accept remote care\n* History of diabetic ketoacidosis or severe hypoglycemia within the past 12 months\n* Presence of retinopathy\n* No retinal imaging performed within the past 12 months\n* Urine albumin-creatinine ratio (uACR) \\> 3 mg\u002Fmmol or estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m² on two occasions over a period of more than 3 months\n* Undergoing dialysis or post-kidney transplantation\n* Cardiovascular disease (excluding hypertension)\n* Neuropathy, foot ulcer, or amputation (foot risk category 1-3)\n* Scheduled hospital outpatient visits for other specialties within the next 12 months\n* Not under specialist diabetes care within the Pirkanmaa Wellbeing Services County (Pirha)",{"count":152,"type":21},125,"24 Months","OBSERVATIONAL","This prospective study evaluates the safety of extending the interval of routine calendar-based follow-up visits from every 12 months to every 24 months in patients with type 1 diabetes who are in good glycemic control and suitable for remote monitoring. The primary outcome is the proportion of patients who maintain good glycemic control during the 24-month follow-up period.\n\nParticipants will attend two in-person visits at baseline (month 0) and at the end of follow-up (month 24), which include a comprehensive clinical examination, assessment of glucose control, and laboratory testing. One remote contact will occur at month 12 for prescription renewal and review of glucose data. Patients may contact their care unit as needed throughout the study. At the baseline and final visits, participants will complete a questionnaire assessing their perceived ability to manage self-care, the safety of the care plan, and their ability to contact their care provider when necessary.",[157,29],"Type 1 Diabetes (T1D)",[159,160,161],"type 1 diabetes","complication","glycemic control","2025-08-18",{"date":164,"type":40},"2025-08-19",{"date":166,"type":21},"2025-10-06",{"date":168,"type":21},"2028-12-31",{"name":170,"class":47},"Tampere University Hospital"]